Show simple item record

dc.contributor.authorYakoub-Agha, I
dc.contributor.authorChabannon, C
dc.contributor.authorBader, P
dc.contributor.authorBasak, GW
dc.contributor.authorBonig, H
dc.contributor.authorCiceri, F
dc.contributor.authorCorbacioglu, S
dc.contributor.authorDuarte, RF
dc.contributor.authorEinsele, H
dc.contributor.authorHudecek, M
dc.contributor.authorKersten, MJ
dc.contributor.authorKohl, U
dc.contributor.authorKuball, J
dc.contributor.authorMielke, S
dc.contributor.authorMohty, M
dc.contributor.authorMurray, John
dc.contributor.authorNagler, A
dc.contributor.authorRobinson, S
dc.contributor.authorSaccardi, R
dc.contributor.authorSanchez-Guijo, F
dc.contributor.authorSnowden, JA
dc.contributor.authorSrour, M
dc.contributor.authorStyczynski, J
dc.contributor.authorUrbano-Ispizua, A
dc.contributor.authorHayden, PJ
dc.contributor.authorKroger, N
dc.date.accessioned2020-01-29T15:17:44Z
dc.date.available2020-01-29T15:17:44Z
dc.date.issued2019en
dc.identifier.citationYakoub-Agha I, Chabannon C, Bader P, Basak GW, Bonig H, Ciceri F, et al. Management of adults and children undergoing CAR t-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE). Haematologica. 2019.en
dc.identifier.pmid31753925en
dc.identifier.doi10.3324/haematol.2019.229781en
dc.identifier.urihttp://hdl.handle.net/10541/622638
dc.description.abstractChimeric antigen receptor T-cells are a novel class of anti-cancer therapy in which autologous or allogeneic T-cells are engineered to express a chimeric antigen receptor targeting a membrane antigen. In Europe, Tisagenlecleucel (KymriahTM) is approved for the treatment of refractory/relapsed Acute Lymphoblastic Leukaemia in children and young adults as well as relapsed/refractory Diffuse Large B-cell Lymphoma; Axicabtagene ciloleucel (YescartaTM) is approved for the treatment of relapsed/refractory high-grade B-cell Lymphoma and Primary Mediastinal B-cell Lymphoma. Both agents are genetically engineered autologous T-cells targeting CD19. These practical recommendations, prepared under the auspices of the European Society of Blood and Marrow Transplantation, relate to patient care and supply chain management under the following headings: patient eligibility, screening laboratory tests and imaging and work-up prior to leukapheresis, how to perform leukapheresis, bridging therapy, lymphodepleting conditioning, product receipt and thawing, infusion of chimeric antigen receptor T-cells, short-term complications including cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome, antibiotic prophylaxis, medium-term complications including cytopenias and B-cell aplasia, nursing and psychological patient support, long-term follow-up, post-authorisation safety surveillance, and regulatory issues. These recommendations are not prescriptive and are intended as guidance in the use of this novel therapeutic class.en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.3324/haematol.2019.229781en
dc.titleManagement of adults and children undergoing CAR t-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)en
dc.typeArticleen
dc.contributor.departmentCHU de Lille, UniversitŽ de Lille, Lille, Franceen
dc.identifier.journalHaematologicaen
dc.description.noteen]
refterms.dateFOA2020-02-03T15:32:46Z


Files in this item

Thumbnail
Name:
31753925.pdf
Size:
2.306Mb
Format:
PDF
Description:
From UNPAYWALL

This item appears in the following Collection(s)

Show simple item record